Q-RNA

Q-RNA was a biotechnology company based in New York City that focused on the development of RNA-based therapeutics and diagnostics. The company specialized in aptamer technology, which involves using short, single-stranded RNA molecules that bind to specific molecular targets with high affinity. Its primary research efforts were directed toward neurodegenerative conditions, specifically targeting the misfolded proteins associated with prion diseases and Alzheimer's disease. Q-RNA's platform was designed to identify ligands that could both detect these pathological proteins for diagnostic purposes and potentially inhibit their aggregation for therapeutic benefit. The company was founded on technology licensed from Columbia University and received backing from prominent venture capital firms. In 2003, Q-RNA was acquired by Archemix Corporation, a move that consolidated significant aptamer-related intellectual property and development programs under one entity.